Gene Signal Will Expand Antisense Ophthalmic Studies With New Funds
This article was originally published in The Pink Sheet Daily
Executive Summary
A topical antisense product, aganirsen, from Switzerland’s Gene Signal is to be evaluated in neovascular glaucoma, age-related macular degeneration and psoriasis following the completion of a Phase III study in corneal graft rejection.